BARDA awards Emergent 10-year, $704M contract for Ebola treatment

Emer­gent BioSo­lu­tions has land­ed a $704 mil­lion con­tract from BAR­DA.

The man­u­fac­tur­er an­nounced the BAR­DA award on Tues­day for a 10-year con­tract to de­vel­op and scale up the pro­duc­tion of the Ebo­la treat­ment Eban­ga. Emer­gent will scale up the man­u­fac­tur­ing of Eban­ga which in­cludes tech trans­fers, sub­mis­sion of a sup­ple­men­tal BLA to the FDA and sta­bil­i­ty stud­ies. Eban­ga was ap­proved by the FDA to treat Ebo­la in 2020.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters